$810.18 Million in Sales Expected for HB Fuller Co (FUL) This Quarter

Share on StockTwits

Wall Street brokerages expect that HB Fuller Co (NYSE:FUL) will post $810.18 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for HB Fuller’s earnings. The highest sales estimate is $815.30 million and the lowest is $803.75 million. HB Fuller posted sales of $678.20 million during the same quarter last year, which would indicate a positive year over year growth rate of 19.5%. The company is expected to announce its next earnings results on Tuesday, January 22nd.

On average, analysts expect that HB Fuller will report full year sales of $3.12 billion for the current financial year, with estimates ranging from $3.09 billion to $3.16 billion. For the next year, analysts anticipate that the business will report sales of $3.25 billion, with estimates ranging from $3.18 billion to $3.29 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover HB Fuller.

HB Fuller (NYSE:FUL) last announced its earnings results on Wednesday, September 26th. The specialty chemicals company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.04). HB Fuller had a return on equity of 12.66% and a net margin of 4.00%. The business had revenue of $770.11 million for the quarter, compared to analysts’ expectations of $784.75 million.

Several equities research analysts recently weighed in on FUL shares. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $57.00 target price on shares of HB Fuller in a research note on Thursday, July 5th. Zacks Investment Research downgraded shares of HB Fuller from a “buy” rating to a “hold” rating in a research note on Monday, September 3rd. Berenberg Bank began coverage on shares of HB Fuller in a research report on Thursday, July 12th. They issued a “buy” rating and a $65.00 price objective on the stock. Robert W. Baird dropped their price objective on shares of HB Fuller from $60.00 to $55.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Deutsche Bank dropped their price objective on shares of HB Fuller from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $61.00.

FUL traded down $1.22 during trading hours on Friday, hitting $51.67. 959,100 shares of the company’s stock were exchanged, compared to its average volume of 409,749. HB Fuller has a 12-month low of $46.62 and a 12-month high of $59.58. The company has a market cap of $2.88 billion, a P/E ratio of 20.54, a PEG ratio of 0.93 and a beta of 1.48. The company has a quick ratio of 1.46, a current ratio of 2.24 and a debt-to-equity ratio of 2.07.

In related news, VP Steven Kenny sold 2,200 shares of the stock in a transaction on Monday, July 30th. The shares were sold at an average price of $56.19, for a total value of $123,618.00. Following the transaction, the vice president now directly owns 30,173 shares of the company’s stock, valued at approximately $1,695,420.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Traci L. Jensen sold 4,508 shares of the stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $57.45, for a total transaction of $258,984.60. The disclosure for this sale can be found here. Corporate insiders own 3.46% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC grew its position in shares of HB Fuller by 77.5% in the 2nd quarter. SG Americas Securities LLC now owns 24,360 shares of the specialty chemicals company’s stock valued at $1,308,000 after buying an additional 10,633 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of HB Fuller by 9.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 398,043 shares of the specialty chemicals company’s stock valued at $21,367,000 after buying an additional 33,956 shares during the last quarter. Engineers Gate Manager LP grew its position in shares of HB Fuller by 106.5% in the 2nd quarter. Engineers Gate Manager LP now owns 46,041 shares of the specialty chemicals company’s stock valued at $2,471,000 after buying an additional 23,750 shares during the last quarter. New York State Common Retirement Fund grew its position in shares of HB Fuller by 233.6% in the 1st quarter. New York State Common Retirement Fund now owns 216,528 shares of the specialty chemicals company’s stock valued at $10,768,000 after buying an additional 151,615 shares during the last quarter. Finally, US Bancorp DE boosted its stake in HB Fuller by 5.6% during the 2nd quarter. US Bancorp DE now owns 97,584 shares of the specialty chemicals company’s stock worth $5,238,000 after purchasing an additional 5,218 shares during the period. 97.65% of the stock is currently owned by hedge funds and other institutional investors.

About HB Fuller

H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, and other specialty chemical products worldwide. The company operates through six segments: Americas Adhesives; EIMEA (Europe, India, Middle East and Africa); Asia Pacific; Construction Products; Engineering Adhesives; and Royal Adhesives.

Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Get a free copy of the Zacks research report on HB Fuller (FUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for HB Fuller (NYSE:FUL)

Receive News & Ratings for HB Fuller Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HB Fuller and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.